rosiglitazone has been researched along with Muscular Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P | 1 |
| Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I | 1 |
| Johnson, TE; Shi, S; Umbenhauer, DR; Zhang, X | 1 |
| Antoniou, T; Berger, P; Kennie, N | 1 |
4 other study(ies) available for rosiglitazone and Muscular Diseases
| Article | Year |
|---|---|
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity | 2009 |
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones | 2005 |
Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
Topics: Adenosine Triphosphate; Animals; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Induction; Fibrinolytic Agents; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ion Channels; Membrane Transport Proteins; Mitochondrial Proteins; Muscle Fibers, Skeletal; Muscular Diseases; Myoblasts, Skeletal; Peroxisome Proliferator-Activated Receptors; Pyrimidines; Rats; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Uncoupling Protein 2 | 2005 |
Elevated creatine kinase and myalgia in a patient taking rosiglitazone.
Topics: Adult; Creatine Kinase; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Muscular Diseases; Pain; Rosiglitazone; Thiazolidinediones | 2007 |